Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen

Wang, Xinning; Tsui, Brian; Ramamurthy, Gopolakrishnan; Zhang, Ping; Meyers, Joseph; Kenney, Malcolm E.; Kiechle, Jonathan E.; Ponsky, Lee; Basilion, James P.

doi:10.1158/1535-7163.mct-15-0722

Cited by 56 publications

(80 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…YC-9 PDT was also well tolerated as indicated by lack of change in body weight. These results collectively demonstrate that YC-9 PDT causes tumor regression and delay in tumor growth without noticeable toxicity at the doses used, which are similar with the in vivo treatment results published by Wang et al [34]…”

Section: Resultssupporting

confidence: 90%

“…Our results along with those of Wang et al [34] lend support to the efficacy of PSMA-targeted PDT using LMW agents.…”

Section: Resultssupporting

confidence: 88%

“…Here we report in more detail the synthesis of this agent and its in vitro and in vivo evaluation for PDT. While this paper was in preparation, Wang et al published PSMA-targeted PDT agents utilizing the PSMA binding Glu-Glu urea moiety [34]. …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A PSMA-targeted theranostic agent for photodynamic therapy

Chen

Chatterjee

Lisok

et al. 2017

Journal of Photochemistry and Photobiology B: Biology

View full text Add to dashboard Cite

Prostate-specific membrane antigen (PSMA) is over-expressed in the epithelium of prostate cancer and in the neovasculature of many non-prostate solid tumors. PSMA has been increasingly used as a target for cancer imaging and therapy. Here we describe a low-molecular-weight theranostic photosensitizer, YC-9, for PSMA-targeted optical imaging and photodynamic therapy (PDT). YC-9 was synthesized by conjugating IRDye700DX N-hydroxysuccinimide (NHS) ester with a PSMA targeting Lys-Glu urea through a lysine-suberate linker in suitable yield. Optical imaging in vivo demonstrated PSMA-specific tumor uptake of YC-9 with rapid clearance from non-target tissues. PSMA-specific cell kill was demonstrated with YC-9 in vitro through PDT in PSMA+ PC3-PIP and PSMA- PC3-flu cells. In vivo PDT in mice bearing PSMA+ PC3-PIP tumors at 4 h post-injection of YC-9 (A total of four PDT sessions were performed, 48 h apart) resulted in significant tumor growth delay, while tumors in control groups continued to grow. PDT with YC-9 significantly increased the median survival of the PSMA+ PC3-PIP tumor mice (56.5 days) compared to other control groups [23.5-30.0 days, including untreated, light alone, YC-9 alone (without light) and non-targeted IRDye700DX PDT treatment groups], without noticeable toxicity at the doses used. This study proves in principle that YC-9 is a promising therapeutic agent for targeted PDT of PSMA-expressing tissues, such as prostate tumors and may also be useful against non-prostate tumors by virtue of neovascular PSMA expression.

show abstract

Section: Resultssupporting

confidence: 90%

“…Our results along with those of Wang et al [34] lend support to the efficacy of PSMA-targeted PDT using LMW agents.…”

Section: Resultssupporting

confidence: 88%

See 1 more Smart Citation

A PSMA-targeted theranostic agent for photodynamic therapy

Chen

Chatterjee

Lisok

et al. 2017

Journal of Photochemistry and Photobiology B: Biology

View full text Add to dashboard Cite

show abstract

“…[315] PSMA-1-targeted PS was used for FGS of prostate tumor resection and intraoperative PDT. Basilion's group synthesized a prostate-specific membrane antigen (PSMA-1)-targeted PS by directly conjugating PSMA-1 with Pc4 and PS approved for clinical use.…”

Section: Fluorescence Imaging-guided Tumor Resection and Intraoperatimentioning

confidence: 99%

Advanced Nanotechnology Leading the Way to Multimodal Imaging‐Guided Precision Surgical Therapy

et al. 2019

View full text Add to dashboard Cite

Surgical resection is the primary and most effective treatment for most patients with solid tumors. However, patients suffer from postoperative recurrence and metastasis. In the past years, emerging nanotechnology has led the way to minimally invasive, precision and intelligent oncological surgery after the rapid development of minimally invasive surgical technology. Advanced nanotechnology in the construction of nanomaterials (NMs) for precision imaging-guided surgery (IGS) as well as surgery-assisted synergistic therapy is summarized, thereby unlocking the advantages of nanotechnology in multimodal IGS-assisted precision synergistic cancer therapy. First, mechanisms and principles of NMs to surgical targets are briefly introduced. Multimodal imaging based on molecular imaging technologies provides a practical method to achieve intraoperative visualization with high resolution and deep tissue penetration. Moreover, multifunctional NMs synergize surgery with adjuvant therapy (e.g., chemotherapy, immunotherapy, phototherapy) to eliminate residual lesions. Finally, key issues in the development of ideal theranostic NMs associated with surgical applications and challenges of clinical transformation are discussed to push forward further development of NMs for multimodal IGS-assisted precision synergistic cancer therapy.

show abstract

“…The study indicates that YC-9 is a promising therapeutic agent for targeted PDT of PSMA-expressing tissues, such as PCa. Similarly, Wang et al synthesized two PSMA-targeting PDT conjugates (PSMA-1-Pc413 and PSMA-1-IR700), both having the potential to aid in the detection and resection of PCa [475]. Lin et al developed a novel nano-platform for targeted delivery of heat, ROS, as well as the heat shock-protein 90 (Hsp90) inhibitor for the treatment of PCa [476].…”

Section: Multimodal Therapy Options For Prostate and Breast Cancermentioning

confidence: 99%

Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications—Focus on Prostate and Breast Cancer

Elgqvist

2017

IJMS

View full text Add to dashboard Cite

Prostate and breast cancer are the second most and most commonly diagnosed cancer in men and women worldwide, respectively. The American Cancer Society estimates that during 2016 in the USA around 430,000 individuals were diagnosed with one of these two types of cancers, and approximately 15% of them will die from the disease. In Europe, the rate of incidences and deaths are similar to those in the USA. Several different more or less successful diagnostic and therapeutic approaches have been developed and evaluated in order to tackle this issue and thereby decrease the death rates. By using nanoparticles as vehicles carrying both diagnostic and therapeutic molecular entities, individualized targeted theranostic nanomedicine has emerged as a promising option to increase the sensitivity and the specificity during diagnosis, as well as the likelihood of survival or prolonged survival after therapy. This article presents and discusses important and promising different kinds of nanoparticles, as well as imaging and therapy options, suitable for theranostic applications. The presentation of different nanoparticles and theranostic applications is quite general, but there is a special focus on prostate cancer. Some references and aspects regarding breast cancer are however also presented and discussed. Finally, the prostate cancer case is presented in more detail regarding diagnosis, staging, recurrence, metastases, and treatment options available today, followed by possible ways to move forward applying theranostics for both prostate and breast cancer based on promising experiments performed until today.

show abstract

Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen

Cited by 56 publications

References 47 publications

A PSMA-targeted theranostic agent for photodynamic therapy

A PSMA-targeted theranostic agent for photodynamic therapy

Advanced Nanotechnology Leading the Way to Multimodal Imaging‐Guided Precision Surgical Therapy

Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications—Focus on Prostate and Breast Cancer

Contact Info

Product

Resources

About